Developing therapeutic monoclonal antibodies at pandemic pace

The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2020-05, Vol.38 (5), p.540-545
1. Verfasser:	Kelley, Brian
Format:	Artikel
Sprache:	eng
Schlagworte:	631/61/51/1568 631/61/51/2314 Agriculture Antibodies, Monoclonal - therapeutic use Antibodies, Viral - therapeutic use Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Biotechnology & Applied Microbiology Clinical Trials as Topic Comment Drug Development - methods Drug Development - standards Epidemics Health aspects Humans Kelley, Brian Life Sciences Life Sciences & Biomedicine Manufacturing Monoclonal antibodies Pandemics Patient safety Product development Productivity Science & Technology Swine influenza Technology, Pharmaceutical Time Factors Virus Diseases - drug therapy Virus Diseases - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/s41587-020-0512-5